Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $103.4 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 28.29% to $103.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.4 million through Dec 2025, down 28.29% year-over-year, with the annual reading at $103.4 million for FY2025, 28.29% down from the prior year.
  • Long-Term Deferred Tax hit $103.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from $101.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $337.8 million in Q2 2021 to a low of $101.7 million in Q3 2025.
  • Historically, Long-Term Deferred Tax has averaged $233.6 million across 5 years, with a median of $243.6 million in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 5.11% in 2022 and later crashed 45.13% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $333.3 million in 2021, then dropped by 14.89% to $283.7 million in 2022, then fell by 25.15% to $212.3 million in 2023, then plummeted by 32.07% to $144.2 million in 2024, then fell by 28.29% to $103.4 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for IRWD at $103.4 million in Q4 2025, $101.7 million in Q3 2025, and $129.5 million in Q2 2025.